← All trials
NCT00516659
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2006
- Primary completion
- Jan 1, 2007
- Completion date
- Dec 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 201
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- IntercellLead sponsor
- Breco Research, Houston, TXOverall official - principal investigator
- Asthma & Allergy Associates, Ithaca, NYOverall official - principal investigator
- Universidad Autonoma De Guadalajara, MexicoOverall official - principal investigator
- AmeriMed Puerto Vallarta, MexicoOverall official - principal investigator
- Hospital Americano, Cancun, MexicoOverall official - principal investigator
- Radiant ResearchOverall official - principal investigator
- Universidad del Valle de GuatemalaOverall official - principal investigator
- Northwest KineticsOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- Twin Cities Clinical Research, MinneapolisOverall official - principal investigator
- Advanced Biomedical ResearchOverall official - principal investigator
- Johns Hopkins UniversityOverall official - principal investigator
- Jean Brown ResearchOverall official - principal investigator
- WCCT GlobalOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.